Company: BLCO
Filing Date: 2025-07-30
Form Type: 10-Q
Source: 0001860742-25-000018
Chunk: 76

Company: Bausch & Lomb Corp
Filing Date: 2025-07-30
Form: 10-Q
Item: Item 8
Chunk 76
---
 was primarily related to: (i) a change in the jurisdictional and seasonal mix of earnings and (ii) discrete tax effects of: (a) a benefit for previously accrued taxes that settled favorably with the Internal Revenue Service and (b) the filings of certain tax returns.See Note 14, “INCOME TAXES” to our unaudited interim Condensed Consolidated Financial Statements for further details.Net loss attributable to Bausch + Lomb CorporationNet loss attributable to Bausch + Lomb Corporation was $62 million and $151 million for the three months ended June 30, 2025 and 2024, respectively, an increase in our results of $89 million and was primarily due to the decrease in income taxes of $161 million, partially offset by the decrease in our operating results of $37 million and increase interest expense of $26 million, each as previously discussed.

43

Six Months Ended June 30, 2025 Compared to the Six Months Ended June 30, 2024Revenues Our revenues were $2,415 million and $2,315 million for the six months ended June 30, 2025 and 2024, respectively, an increase of $100 million, or 4%. The increase was attributable to: (i) increased volumes of $127 million across each of our segments, (ii) incremental sales attributable to acquisitions of $12 million, within our Surgical segment and (iii) the favorable impact of foreign currencies of $2 million. The increases in revenue were partially offset by: (i) decreased net realized pricing of $38 million, driven by our Pharmaceuticals segment and (ii) the impact of divestitures and discontinuations of $3 million, relating to the discontinuation of certain products within our Vision Care segment.The following table presents segment revenues, segment revenues as a percentage of total revenues and the period-over-period changes in segment revenues for the six months ended June 30, 2025 and 2024. 20252024Change(in millions)AmountPct.AmountPct.AmountPct.Segment RevenuesVision Care$1,409 58 %$1,332 57 %$77 6 %Pharmaceuticals576 24 %577 25 %(1)— %Surgical430 18 %406 18 %24 6 %Total revenues$2,415 100 %$2,315 100 %$100 4 %Constant